Technology | October 17, 2011

Avinger Wildcat Catheter Sees First Michigan Use

October 17, 2011 — The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) has become the first cardiac care facility in Michigan to successfully open a patient's blocked artery with a breakthrough technology similar to an electrically powered "corkscrew drill." The technique painlessly removes the plaque buildup which causes peripheral artery disease (PAD).

The 45-minute procedure — conducted by CVI Director of Endovascular Medicine Mahir D. Elder, M.D. — was successful in restoring uninterrupted blood flow through the patient's femoral artery. The artery in question had been obstructed with a 100 percent plaque blockage caused by PAD.

"Yesterday's successful procedure, completed without invasive surgery and requiring less than an hour, is a significant step forward in the treatment of arterial blockages triggered by chronic arterial disease," said Elder. "For the first time in Michigan, a patient with a totally blocked artery was able to benefit from a powerful new technology that can remove even the most severe blockages – and without the cutting or stitches that are part of traditional bypass surgery.

"This patient was in danger of losing a foot – but thanks to this new procedure that we will now be using with PAD patients from all across Detroit and Southeast Michigan, that risk has been eliminated and she'll be going home in a day or two."

The patient who underwent the procedure was a 50-year-old postal worker from the Detroit suburb of Livonia, said Elder. "This patient had consulted with several physicians in recent years," he added, "and she'd been told that her only option was invasive surgery to bypass the damaged artery – which was 100 percent blocked by PAD-related plaque.

"Fortunately, however, the new 'corkscrew catheterization' technique that was unveiled at CVI yesterday doesn't require surgery at all. Instead, this state-of-the-art procedure uses a drill-like catheter powered by a small electric motor to remove the plaque-buildup on the walls of the artery, quickly and painlessly."

The new U.S. Food and Drug Administration (FDA)-cleared catheterization tool, known as the Avinger Wildcat Catheter, uses the automated tip rotation produced by a compatible hand-held motor (the Avinger Juicebox) to open up the artery. The tip of the drill is inserted through the catheter directly into the affected artery.

Because the technique doesn't involve any surgery, most patients are spared the pain, risk of infection and extended healing time that usually result from a surgical operation.

The successful operation was a highly promising breakthrough in caring for patients with PAD, said CVI President Theodore L. Schreiber, M.D. "PAD affects up to 20 million Americans today, according to the latest research data, and many of those patients are struggling with severe arterial blockages that often used to require amputation of affected limbs, and especially of the legs and feet," he said.

For more information: www.dmc.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Overlay Init